 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
20188 News |  |
| «12...197198199200201202203204205206207208209» |
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: HOPE 3: Special Investigation (Follow-up Survey of the Study of Adalimumab (D2E7) for Prevention of Joint Destruction in Patients With Rheumatoid Arthritis in Japan (M06-859 (NCT00870467)) (clinicaltrials.gov) - Oct 24, 2012
P=N/A, N=220, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment change: ADMIRE: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (clinicaltrials.gov) - Oct 23, 2012
P4, N=33, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=50 --> 33
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: ADMIRE: A Pilot Study of the Feasibility of Discontinuation of Adalimumab in Stable Rheumatoid Arthritis Patients in Clinical Remission (clinicaltrials.gov) - Oct 23, 2012
P4, N=33, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=50 --> 33 Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial, PK/PD data: A Study in Rheumatoid Arthritis (RA) Patients to Compare Two Formulations of Adalimumab for Pharmacokinetic, Pharmacodynamic and Safety (clinicaltrials.gov) - Oct 21, 2012
P2, N=100, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Special Investigation in Patients With Rheumatoid Arthritis (HOPEFUL III Study), a Follow-up Survey of Study P12-069 (clinicaltrials.gov) - Oct 18, 2012
P=N/A, N=125, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Olumiant (baricitinib) / Incyte, Eli Lilly
New P3 trial: RA-BEAM: A Study in Moderate to Severe Rheumatoid Arthritis (clinicaltrials.gov) - Oct 17, 2012
P3, N=1280, Recruiting, Sponsor: Eli Lilly and Company
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 8, 2012
P2, N=10, Recruiting, Sponsor: Wayne State University
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Addition of Modulators of Homocysteine to Adalimumab Therapy in the Treatment of Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - Oct 2, 2012
P2, N=10, Recruiting, Sponsor: Wayne State University
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Combination therapy: REACT2: Enhanced Algorithm for Crohn's Treatment Incorporating Early Combination Therapy (clinicaltrials.gov) - Sep 30, 2012
P4, N=1200, Enrolling by invitation, Sponsor: University of Western Ontario, Canada
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Study of Adalimumab (HUMIRA®) in Patients With Moderate to Severe Psoriasis (PS) in Spain (PROMISE) (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=547, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- || Taltz (ixekizumab) / Eli Lilly, Japan Tobacco
New P3 trial: SPIRIT-P1: A Study of Ixekizumab in Participants With Active Psoriatic Arthritis (clinicaltrials.gov) - Sep 25, 2012
P3, N=412, Recruiting, Sponsor: Eli Lilly and Company
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, HEOR: Greek Study of the Quality of Life in Patients With Psoriasis Treated With Adalimumab (clinicaltrials.gov) - Sep 25, 2012
P=N/A, N=500, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: MAINTAIN: Retention Rates of Adalimumab, Etanercept and Infliximab as First and Second-Line Biotherapy in Patients With Rheumatoid Arthritis in Daily Practice (clinicaltrials.gov) - Sep 23, 2012
P4, N=780, Completed, Sponsor: Pfizer
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change, HEOR: AGIL: Safety and Effect on Quality of Life/Work Productivity of Humira in Patients With Rheumatoid Arthritis (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=4500, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed N=2500 --> 4500
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) (clinicaltrials.gov) - Sep 13, 2012
P=N/A, N=752, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=2500 --> 4500 Active, not recruiting --> Completed
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Greek Study on Work Productivity and Sleep in Patients With Rheumatic Diseases Treated With Adalimumab (clinicaltrials.gov) - Aug 29, 2012
P=N/A, N=500, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) (clinicaltrials.gov) - Aug 26, 2012
P3, N=54, Not yet recruiting, Sponsor: Peter Higgins
- ||||| Humira (adalimumab) / Eisai, AbbVie
Trial initiation date: Long Term Open Label Continuation Study (clinicaltrials.gov) - Aug 23, 2012
P3, N=846, Completed, Sponsor: Abbott
Recruiting --> Active, not recruiting Initiation date: Feb 2000 --> Jul 2000
- ||| clazakizumab (CSL300) / CSL Behring
Enrollment closed, P2b data: Phase IIB Rheumatoid Arthritis Dose Ranging Study for BMS-945429 in Subjects Who Are Not Responding to Methotrexate (clinicaltrials.gov) - Aug 22, 2012
P2b, N=406, Active, not recruiting, Sponsor: Bristol-Myers Squibb
Initiation date: Feb 2000 --> Jul 2000 Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
New P3 trial, HEOR, Combination therapy: FOURIER: Adalimumab in the Treatment of Chronic Pouchitis (clinicaltrials.gov) - Aug 20, 2012
P3, N=24, Recruiting, Sponsor: Odense University Hospital
- Enrollment open: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - Aug 20, 2012
P4, N=190, Recruiting, Sponsor: Spanish Clinical Pharmacology Society
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / AbbVie
Enrollment change: Switching Anti-TNF-Alpha Agents in Rheumatoid Arthritis (RA) (clinicaltrials.gov) - Aug 16, 2012
P4, N=13, Terminated, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=144 --> 13
- ||| Tremfya (guselkumab) / J&J
Enrollment closed: X-PLORE: A Study to Evaluate CNTO 1959 in the Treatment of Patients With Moderate to Severe Plaque-type Psoriasis (clinicaltrials.gov) - Aug 12, 2012
P2, N=293, Active, not recruiting, Sponsor: Janssen Inc.
N=144 --> 13 Recruiting --> Active, not recruiting
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Special Investigation in Patients With Psoriasis Vulgaris and Psoriatic Arthritis (All Patients Investigation) (clinicaltrials.gov) - Aug 11, 2012
P=N/A, N=752, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=500 --> 752
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: A 3-year Study Following up Patients With Moderate to Severe Rheumatoid Arthritis Treated With Humira in Greece (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=566, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
N=500 --> 752 Active, not recruiting --> Completed
- ||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: Surveillance of Humira Injection in Korean Patients (clinicaltrials.gov) - Aug 9, 2012
P=N/A, N=1779, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Enrolling by invitation --> Completed
- Humira (adalimumab) / AbbVie
Trial withdrawal, HEOR: ELAN: Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: Abbott
Enrolling by invitation --> Completed Not yet recruiting --> Withdrawn
- Humira (adalimumab) / AbbVie
Enrollment change, HEOR: ELAN: Safety and Effectiveness and Effect on Quality of Life and Work Productivity of Humira in Patients With Psoriatic Arthritis in Clinical Routine (clinicaltrials.gov) - Aug 7, 2012
P=N/A, N=0, Withdrawn, Sponsor: Abbott
Not yet recruiting --> Withdrawn N=2500 --> 0
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Enbrel (etanercept) / Pfizer, Amgen, Humira (adalimumab) / Eisai, AbbVie
Clinical: TNF-alfa Inhibitors and Antibody Production in Patients With Psoriasis (clinicaltrials.gov) - Aug 2, 2012
P=N/A, N=60, Recruiting, Sponsor: University Hospital, Gentofte, Copenhagen
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion: FA-Crohn: Safety and Tolerability of FITC-Adalimumab Administration During Confocal Laser Endomicroscopy of the Gut (clinicaltrials.gov) - Jul 29, 2012
P1/2, N=25, Completed, Sponsor: University of Erlangen-Nürnberg Medical School
N=2500 --> 0 Recruiting --> Completed
- Humira (adalimumab) / AbbVie
Enrollment open: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jul 26, 2012
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Not yet recruiting --> Recruiting
- ||||||| Humira (adalimumab) / AbbVie
Trial completion: DORA: Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis (clinicaltrials.gov) - Jul 24, 2012
P3, N=84, Completed, Sponsor: Assistance Publique - H
Not yet recruiting --> Recruiting Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, IO biomarker: Mechanism of Action Study for Psoriasis (clinicaltrials.gov) - Jul 19, 2012
P4, N=33, Active, not recruiting, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jul 18, 2012
P3, N=425, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation (clinicaltrials.gov) - Jul 17, 2012
P4, N=50, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 8, 2012
P3, N=540, Enrolling by invitation, Sponsor: AbbVie (prior sponsor, Abbott)
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: INTASAH: Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing (clinicaltrials.gov) - Jul 5, 2012
P4, N=30, Recruiting, Sponsor: Regionshospitalet Silkeborg
Recruiting --> Active, not recruiting N=25 --> 30
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis (clinicaltrials.gov) - Jul 5, 2012
P3, N=69, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=25 --> 30 Active, not recruiting --> Completed
- |||| Humira (adalimumab) / AbbVie
Enrollment open: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Jun 28, 2012
P4, N=100, Recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence: Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=7, Completed, Sponsor: Wake Forest University
Not yet recruiting --> Recruiting N=20 --> 7
- Humira (adalimumab) / Eisai, AbbVie
Trial completion, Adherence: Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=7, Completed, Sponsor: Wake Forest University
N=20 --> 7 Recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: POPART: Adalimumab for the Management of Post-operative Crohn's Disease (CD) (clinicaltrials.gov) - Jun 25, 2012
P3, N=100, Not yet recruiting, Sponsor: Tel-Aviv Sourasky Medical Center
- Humira (adalimumab) / AbbVie
Trial initiation date: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jun 12, 2012
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Initiation date: Mar 2012 --> Jul 2012
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Adalimumab for Inflammatory Osteoarthritis (clinicaltrials.gov) - Jun 11, 2012
P1/2, N=20, Completed, Sponsor: University of Alberta
Initiation date: Mar 2012 --> Jul 2012 Active, not recruiting --> Completed
- Biomarker, Enrollment open: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 11, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Surgery: FACC: Anal Crohn Fistula Surgery (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=180, Recruiting, Sponsor: French Society of Coloproctology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Clinical: Causes of Visual Loss in Retinal Disease (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=2000, Enrolling by invitation, Sponsor: Royal Surrey County Hospital
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Enrollment change: Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease (clinicaltrials.gov) - Jun 1, 2012
P1/2, N=41, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=75 --> 41
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Trial completion: Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease (clinicaltrials.gov) - Jun 1, 2012
P1/2, N=41, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=75 --> 41 Recruiting --> Completed
- Clinical: Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity (clinicaltrials.gov) - May 31, 2012
P=N/A, N=398, Recruiting, Sponsor: University Hospital, Montpellier